Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + Obinutuzumab + Venetoclax in Treatment-naïve MCL
NCT07719556Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib, obinutuzumab and venetoclax in mantle cell lymphoma (MCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete Response Rate. Started Jul 2026; status: recruiting.
02
Drugs
orelabrutinibobinutuzumabvenetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07719556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719556.